We determined bone marrow karyotype at diagnosis in four female acute myeloid leukemia (AML) or myelodysplasia patients, aged between 52 and 56 years. In each case, we observed chromosome rearrangement involving the same 4q24 band. Three patients had a balanced reciprocal translocation as the sole abnormality -t(3;4)(q26;q24), t(4;5)(q24;p16) and t(4;7)(q24;q21) -and the fourth had del(4)(q23q24), þ 4. We used a set of 4q BAC probes for fluorescent in situ hybridization (FISH) in these four cases. We found a 4q24 submicroscopic deletion in all three translocations, with a common deletion of approximately 0.5 Mb. In three cases, we concluded that rearrangement occurred in an early hematopoietic stem cell, as it was detected, in mosaic with a normal karyotype, in a fraction of remission bone marrow cells, peripheral T and B lymphocytes, malignant lymph node T-lymphoma cells in one case and B-lymphoblastoid cell lines established in two cases. Moreover, one of 10 additional AML patients tested by FISH had a normal karyotype and deletion of one of the commonly deleted probe sequences. A tumor suppressor gene may therefore be involved, especially as two patients developed malignant lymphoma at the same time as myeloid proliferation.
Introduction
A total of 50-80% of hematopoietic malignancies are characterized by one to several clonal chromosome alterations, detected exclusively in tumor cells. 1 An increasing number of such alterations have been shown to be recurrent and to be specific, or at least not random; they are thought to play a key role in leukemic transformation or progression. 2 Conversely, some cases display a single somatic chromosome change not known to be recurrent or specific. If such changes are potentially viable, as is the case for a balanced translocation/ inversion, or slightly unbalanced, then the karyotype of nontumoral dividing cells should be studied to search for a possible constitutional origin.
Under these conditions, it is generally straightforward to distinguish between clonal and constitutional genomic changes. However, the situation is sometimes complicated by the multistep nature of carcinogenesis, and by genomic changes occurring in a premalignant blood stem cell indistinguishable from a normal cell. 3 Chromosomal abnormalities related to the malignant phenotype may occur at various stages of hematopoietic maturation. In acute myeloid leukemia (AML) and in myelodysplastic syndromes (MDS), primary leukemic events were initially thought to concern a committed myeloid progenitor in most cases. [4] [5] [6] However, there is increasing evidence to suggest that, in a number of cases, the primary chromosome change probably occurred in a very primitive hematopoietic stem cell able to differentiate into myeloid and lymphoid cells. 3, [7] [8] [9] [10] We report here cytogenetic investigations of four AML or MDS patients. Tumor cells from three of these four patients carried an apparently balanced translocation involving a similar 4q breakpoint as the sole karyotypic abnormality. The fourth patient displayed a small 4q deletion. We consider these four cases together because they share unusual features, such as the unexpected 4q microdeletion, the extension of the chromosome abnormality to other presumably normal hematopoietic tissues tested in three of the four cases and the occurrence, in two patients, of malignant lymphoma, progressing in parallel to myeloid proliferation. All these features are consistent with mosaic microdeletion occurring in a very early hematopoietic stem cell, leading to the loss of one allele of an uncharacterized tumor suppressor gene. The detection of a similar deletion in an additional AML patient with normal bone marrow karyotype raised additional questions concerning the frequency and significance of such changes.
Materials and methods

Case reports
Patient 1, a 56-year-old woman, was admitted for AML-M4, without hyperleukocytosis or organomegaly. Her immunophenotype showed CD33 þ , CD13 þ and CD56 þ myeloid proliferation. The patient was included in the GOELAM protocol, and complete remission was achieved by treatment with idarubicin and cytarabine, followed by consolidation treatment with mitoxantrone and cytarabine. At 3 1 2 months after the induction of chemotherapy, when the patient was still in remission, a monoclonal B-cell lymphoid population appeared in the bone marrow. The immunophenotype of this population was DR þ , CD10 þ , CD19 þ , CD20 þ , with intracytoplasmic immunoglobulin lambda chains. This population was considered to correspond to malignant B-cell lymphoma and no extramedullar site was detected. After a second course of consolidation treatment, complete remission was achieved for both AML and lymphoma. The patient underwent two autologous peripheral stem cell transplantations separated by 2 months. She was still in remission 2 years after diagnosis.
Patient 2, a 53-year-old woman, consulted for myelodysplasia without excess blasts, which had continued for about 10 years, and for bilateral cervical and left axillar lymph node swellings that had appeared 1 year before. Hemoglobin concentration was 11.4 g/dl, white blood cell count was 3.6 Â 10 9 /l and platelet count was 86 Â 10 9 /l. Bone marrow showed degranulation of granulocytes, without excess blasts. Successive biopsies of the left and right cervical lymph nodes led to the diagnosis of malignant T-cell lymphoma, coexisting with myelodysplasia. Skin lesions were detected on the limbs 3 months later. The immunophenotype of the T-cell population was CD2 þ , CD4 þ , CD3À, with clonal rearrangement of the gamma T-cell receptor gene. The patient received eight courses of CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone).
Patient 3, a 53-year-old woman, was admitted for acute myeloid leukemia with hyperleukocytosis, without organomegaly. White blood cell count was 79.6 Â 10 9 /l, with 88% blast cells. Hemoglobin concentration was 10.5 g/dl; platelet count was 82 Â 10 9 /l. Bone marrow was hypercellular, with 94.5% myeloblasts classified as AML-M1. The immunophenotype of the tumor cells was DR þ , CD34À, CD33 þ , CD13 þ , CD117À, CD4 þ . These cells were myeloperoxidase-negative. No overproduction of P-glycoprotein was observed. The patient was included in the EORTC AML12 protocol and treated with daunorubicin, cytarabine and etoposide. Partial remission was achieved. Despite consolidation cures with idarubicin and cytarabine, followed by high-dose cytarabine, peripheral blast cells persisted. The patient died from sepsis and hyperleukocytosis, 8 months after diagnosis.
Patient 4, a 54-year-old woman, presented with 70% blast cells in bone marrow, classified as AML-M4. Complete remission was obtained by treatment with cytarabine and daunorubicin, followed by autologous bone marrow transplantation. The patient is still in complete remission.
Only patient 3 had a history of cancer. She had undergone surgical ablation of a frontal nonmalignant astrocytoma 5 years before.
Cytogenetic analysis
Bone marrow karyotypes were studied from short-term (24-48 h) cultures in the absence of mitogen, at onset and during the course of the disease.
Peripheral blood cells taken during remission were cultured for 72-96 h with phytohemagglutinin A (PHA), for constitutional karyotype determination in stimulated T lymphocytes. We studied B-cell populations by culturing whole blood for 72 h with 12-O-tetradecanoylphorbol-13-acetate/lipopolysaccharide from Escherichia coli (TPA/LPS).
Fibroblasts from a skin biopsy sample were cultured for patient 1.
For patients 1 and 2, continuous polyclonal B-lymphoblastoid cell lines were successfully established from peripheral blood lymphocytes cultured in the presence of Epstein-Barr virus (EBV).
Exponential cultures were centrifuged and pellets were subjected to shock by incubation in hypotonic KCl. They were then fixed in methanol-acetic acid, spread on clean slides and air dried. Metaphases were photographed and analyzed after R-banding by heat denaturation. Chromosome abnormalities were described as recommended by the ISCN. Hybridization was performed at 371C, for 12-48 h, under a coverslip. Slides were examined under UV light on a Zeiss photomicroscope. Digital images were captured with a Cohu camera. Breakpoint location was studied exclusively on metaphases. A common deletion zone was delimited, and interphase dual-color fluorescent in situ hybridization (FISH) experiments with two probes hybridizing within the deleted zone were then performed to evaluate the extent of the deletion in nondividing cells. The cutoff value ( þ 3 s.d.) was estimated to be o4% in normal controls.
Results
Sequential banding studies for whole chromosomes are summarized in Table 1 .
In three patients, R-banded bone marrow karyotype at diagnosis showed an apparently balanced reciprocal translocation in 100% of the metaphases, with no other detectable rearrangement ( Figure 1a, b and d) . The same 4q24 breakpoint was involved in all three cases, in association with 3q26 in one patient, 5p16 in another and 7q21 in the third. None of these translocations are known to be recurrent clonal rearrangements. The fourth patient had trisomy 4 on diagnosis, but one of the homologs displayed a small 4q23-q24-25 deletion (Figure 1c ). Whole chromosome 4 painting eliminated a 4q insertion into another chromosome.
We searched for potential constitutional abnormalities by studying karyotypes in peripheral lymphocytes from the four patients. These cells were collected in the remission phase and stimulated with PHA. Unexpectedly, three of the four rearrangements were found in a variable proportion of stimulated T lymphocytes, in mosaic with cells displaying a normal karyotype. Similar results were obtained with TPA/LPSstimulated B lymphocytes. Moreover, the rearrangement persisted in 100% of metaphases from patients 1 and 2, even during remission. Only partial remission was obtained in patient 3, with the disappearance of trisomy 4 but the persistence of del(4q). In patient 4 only, the translocation was restricted to the leukemic cells and was undetectable in bone marrow at remission and in other hematopoietic populations.
Patient 2 developed T NHL in parallel with MDS; chromosome analysis showed that t(4;5) was also present in lymphoid cells studied from right and left cervical lymph node biopsies.
A skin biopsy sample from patient 1 was also cultured to evaluate the extent of mosaicism. A normal karyotype was found in all fibroblast metaphases analyzed.
Finally, in patients 1 and 2, carrying t(3;4) and t(4;5), respectively, polyclonal lymphoblastoid cell lines (LCL) were established from EBV-immortalized peripheral B lymphocytes. In both cases, the rearrangement was found in most cells. We
were unable to establish an LCL for patient 3, probably because of severe lymphopenia at that time. We tried to localize precisely the 4q breakpoint of the translocations by hybridizing BAC probes spanning 4q22.3-4q27 to malignant bone marrow cell metaphases. Results confirmed the 4q24 breakpoint of the three translocations. As expected, centromeric probes were on der(4) and telomeric probes were on the other derivative of the translocation. However, all cases displayed an unexpected localized interstitial deletion associated with the 4q24 breakpoint. Nearcontiguous BAC probes covering the three chromosomal deletions defined a common region of deletion binding to two contiguous DNA probes, 356L5 and 16G16. In patient 2, FISH analysis showed a deletion on both chromosomes 4; centromeric 4q24 region hybridizing with 356L5 was deleted on nonrearranged chromosome 4, whereas telomeric 4q24 region hybridizing with 16G16 and more distal 642P17 and 788K3 probes was deleted on translocated chromosome 4. In patient 4, partial deletion was observed with 16G16, which gave a signal of only half the normal intensity (Figure 1e and f) . In del(4q), the deleted area extended from above the more proximal 4q22.3 probe tested to proximal 4q25, between 752J12 and 66J6. Based on the size of the BAC probes, the commonly deleted region is approximately 0.5 Mb long (Figure 2) .
In patient 4, who presented trisomy 4 at diagnosis, FISH analysis showed a deletion in only one of the three homologs, consistent with banding results.
The extent of the deletion was quantified in the analyzed hematopoietic tissues, by dual-color FISH analysis of 200-300 interphase cells with probes 356L5 and 16G16. Consistent with R-banding, deletion was detected in all tissues displaying rearranged metaphases (Table 1) . 
Recurrent 4q24 deletion in hematopoietic malignancy F Viguié et al
As the deletion may, hypothetically, have preceded the three translocations, we carried out a metaphase FISH study on mitogen-stimulated lymphocyte cultures from patients 1 and 2, which contained a high proportion of normal metaphases. In both cases, dual-color FISH with deleted probes yielded two red-green signals on both chromosome 4 homologs in all nontranslocated metaphases observed, providing strong evidence for the simultaneous occurrence of translocation and deletion. A similar pattern was observed in lymphocyte cultures from patient 3, with del(4)(q22.3q24).
We tried to determine whether the 4q24 submicroscopic deletion was a recurrent feature of adult AML by testing a series of bone marrow samples from two women and eight men, aged 35-79 years at AML diagnosis, by FISH, with probes from the common deleted region. Bone marrow karyotypes were normal in four cases, with the other six patients displaying inv(16)(p13q22), þ 6 (one case), þ 11 (one case), t(11;19)(q23;p13.3) (one case), ÀY, þ 7, þ 20 (one case), t(2;3)(p2?3;q2?6), À7 (one case) and þ r(?) (one case). No deletion was detected in nine patients. However, one 74-yearold man with a normal karyotype displayed a heterozygous deletion corresponding to the 356L5 BAC probe in all observed mitoses and in 83% of interphase cells. Unfortunately, only leukemic bone marrow was available for this patient, so we were unable to evaluate the possible expansion of the deletion to nonleukemic blood cell populations.
Discussion
We described four female AML/MDS patients with tumor cells displaying similar 4q abnormalities not previously reported to be specific or recurrent. The same 4q24 band was involved in three apparently balanced translocations between 4q and a variable partner chromosome, and in a localized 4q22.3-q24 deletion. However, metaphase FISH analyses revealed a 4q deletion in all four cases, involving deletion of a common 4q24 region. These rearrangements, initially observed in tumor cells at diagnosis, were also detected, in three of the four patients, in a fraction of all other presumably normal hematopoietic populations tested.
Detection of the same chromosomal abnormality in malignant and nonmalignant cells implies either constitutional mosaicism or the alteration of a primitive hematopoietic stem cell, resulting in somatic mosaicism, presumably restricted to the hematopoietic tissue. Constitutional mosaic aneuploidies, such as trisomy 8 or 21, have been implicated in leukemia, 12 but nothing comparable has been reported for structural abnormalities. Familial balanced translocations predisposing subjects to cancer have been described, 13 but no such involvement has ever been demonstrated with certainty in the development of hematopoietic malignancies. [14] [15] [16] We obtained no evidence for constitutional mosaicism extending to nonhematopoietic tissues. However, these patients may display a presumably constitutional cryptic deletion preceding and favoring the three reciprocal translocations. Recent genomic explorations of normal study populations by CGH array analysis have shown large polymorphic segmental deletions or duplications of up to 1 Mb, even within coding regions. 17, 18 Some authors have argued that such variants should favor translocations. These polymorphic variations were similar in size to the deletions we observed, which could be considered as polymorphisms. However, in the case of our translocations, metaphase FISH analyses in tissues expressing the mosaic showed that the deletion occurred at the time of the translocation, as normal metaphases had a FISH pattern with no deletion. This situation is similar to what is observed in chronic myeloid leukemia, in which large deletions associated with t(9;22)(q34;q11) have been detected by FISH in a subset of patients with poor prognosis. 19 A similar phenomenon was observed in AML patients with t(8;21)(q22;q22) or inv (16)(p13q22). 20 In all cases analyzed, the deletion occurred at the same time as translocation or inversion.
Detection of the same nonconstitutional clonal chromosome rearrangement in a subset of myeloid, B and T cells suggests that this rearrangement occurred in a primitive multipotent hematopoietic stem cell and served as a first step favoring progression to the development of leukemia. In the AML-M2 subgroup with t(8;21)(q22;q22) and AML1-ETO fusion, chimeric transcripts were detected in patients in long-term remission. Phenotypic and molecular analysis of purified fractions from patients displaying leukemia progression or in remission showed that AML1-ETO transcripts were present in the myeloid compartment, but also in a fraction of stem cells, monocytes and B lymphocytes. 10 del(4)(q23q24) t(4;7)(q24;q21)
der (4) der (7) e f c d a b Figure 1 Partial R-banded karyotype of (a) t(3;4)(q26;q24) (patient 1), (b) t(4;5)(q24;p14) (patient 2), (c) del(4)(q22.3q24) (patient 3) and (d) t(4;7)(q24;q21) (patient 4). FISH analysis in patient 4 (e, f): 16G16 (4q24) probe hybridization on leukemic cells from patient 4 with t(4;7)(q24;q21). Note that the intensity of the signal indicated by an arrow on der (7) is approximately half that of the normal chromosome 4. The same pattern is observed in interphase cells (arrows indicate the signal concerned). 
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F Viguié et al such as þ 8 or À7 in myeloid leukemic cells is also present in multilineage precursors and in B-lymphoid cells. As none of these patients developed lymphoid proliferation in addition to myeloid proliferation, additional events, occurring exclusively in the myeloid lineage, are required for leukemic progression. In our study, the chromosome rearrangement was detected in all hematopoietic compartments, but predominantly in myeloid populations. A study of the X-inactivation pattern in bone marrow cells from elderly female patients showed a skewed distribution, with a tendency of one of the two lineages to predominate with age. 21 It has been suggested that this may be due to a selective advantage conferred by X-linked genetic factors on the one active chromosome. Del/t(4q24) should also confer a selective advantage on myeloid cells, favoring the extension of the rearrangement in bone marrow. However, myeloid selection does not seem to be exclusive, as two patients also developed lymphoid proliferation.
Regardless of the stage at which mosaicism occurs, unresolved questions remain concerning the role of such mosaicism in cancer development. A submicroscopic interstitial deletion del(4)(q12q12) has recently been described in hypereosinophilic syndrome. It results in a FIP1L1-PDGFRA fusion, encoding a chimeric tyrosine kinase, and makes possible a response to imatinib mesylate therapy. 22 Such a model was unlikely here, as the heterogeneity of 4q24 breakpoints and of partner chromosomes for translocation are not consistent with the fusion gene hypothesis. The inactivation of a cancer gene with tumor suppressor activity seems more likely, although no known cancer gene has been characterized in the common region of deletion delineated by the two BAC probes. The deletion of one allele in premalignant stem cells should be the first event in a multistep process involving inactivation of the second allele and, possibly, other molecular or karyotypic alterations. The development of malignant lymphoma almost simultaneously with myeloid proliferation in two of the four patients provides strong support for this hypothesis. In patient 4, both alleles were probably altered at a much later stage of maturation because only myeloid tumor cells carried the translocation. The detection of an identical deletion in another AML patient with a normal bone marrow karyotype is consistent with the frequent involvement of the deleted region in the development of leukemia, without a karyotypic abnormality necessarily being detected.
